Risk of cardiovascular events and mortality associated with LDL and non-HDL cholesterol levels after statin initiation for primary prevention: A multiregional cohort study
Risk of Cardiovascular Events and Mortality Associated with LDL and Non-HDL Cholesterol Levels After Statin Initiation for Primary Prevention: A Multiregional Cohort Study This article examines recent research published in PLOS Medicine analyzing the associations between cholesterol levels and health outcomes in patients beginning statin therapy for primary prevention of cardiovascular disease.…
Transforming pandemic influenza antiviral stockpiling using a capacity-based approach: A modeling study
Transforming Pandemic Influenza Antiviral Stockpiling: A Capacity-Based Model Assessment Source: PLOS Medicine, November 3, 2026 What is Established Global preparedness for pandemic influenza has historically relied on maintaining large antiviral drug stockpiles, with coverage targets often set at approximately 25% of the population in many high-resource countries such as the United States,…
Human medicines European public assessment report (EPAR): Bildyos, denosumab, Date of authorisation: 17/09/2025, Revision: 5, Status: Authorised
What is established Bildyos is a biosimilar medicine containing the active substance denosumab, authorized for use in the European Union as of September 17, 2025. It is approved to treat osteoporosis in postmenopausal women and in men with increased risk of fractures, as well as bone loss in patients receiving corticosteroid treatment…
Human medicines European public assessment report (EPAR): Vlustozik (previously Ibuprofen Gen.Orph), ibuprofen, Date of authorisation: 16/02/2024, Revision: 5, Status: Authorised
What is established The European Medicines Agency (EMA) authorized the use of Vlustozik, a generic injectable ibuprofen medicine, on February 16, 2024. This medicine is indicated for treating patent ductus arteriosus (PDA) in premature newborns born before 34 weeks gestational age. PDA is a condition where a critical fetal blood vessel fails…
Human medicines European public assessment report (EPAR): Veanibek (previously Miglustat Gen.Orph), miglustat, Date of authorisation: 09/11/2017, Revision: 13, Status: Authorised
What is established Miglustat is a medicine used in the treatment of rare inherited diseases characterized by the build-up of certain fatty substances called glycosphingolipids. Specifically, it is indicated for adults with mild to moderate type-1 Gaucher disease who cannot undergo standard enzyme-replacement therapy, and for patients of all ages with Niemann-Pick…
Trends in the incidence of childhood type 1 diabetes after the COVID-19 lockdown in Finland: An observational study
Trends in Childhood Type 1 Diabetes Incidence in Finland After COVID-19 Lockdown: Evidence Overview A recent observational study published in PLOS Medicine investigates how the incidence of childhood type 1 diabetes (T1D) in Finland evolved following the COVID-19 lockdown, offering insights into the complex dynamics between the pandemic, societal restrictions, and autoimmune…
Addressing threats to validity in large dataset research
Addressing Validity Threats in Large Dataset Biomedical Research: An Evidence-Based Overview In the era of big data, biomedical research increasingly leverages massive integrated datasets combining clinical, genomic, environmental, and social information. While these datasets enable analyses of complex phenomena with unprecedented power, they simultaneously amplify methodological challenges that threaten the validity of…
Disillusion runs deep among young Americans
Disillusionment Among Young Americans: An Evidence Dossier What is Established Recent polling data reveals significant disillusionment among young Americans, particularly those aged 18 to 29, regarding their economic prospects and the health of American democracy. The Harvard Kennedy School’s Institute of Politics (IOP) conducted a biannual poll demonstrating that more young respondents…
About half of drinkers on GLP-1s say they imbibed less
What is established Glucagon-like peptide-1 receptor agonists (GLP-1s) are medications primarily prescribed for treating type 2 diabetes and obesity. These drugs have gained substantial popularity due to their weight loss efficacy. Historical evidence confirms that medications exist to treat alcohol use disorder, such as disulfiram, but these have been underutilized with only…
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 26 – 29 October 2026
Pharmacovigilance Update: PRAC Reviews on Deanxit and Human Normal Immunoglobulin Medicines – October 2026 This evidence dossier summarizes key findings and ongoing assessments from the Pharmacovigilance Risk Assessment Committee (PRAC) meeting held from 26 to 29 October 2026, as reported by the European Medicines Agency (EMA). Two main safety reviews were initiated:…